CP
YMAB

Caligan Partners’s Y-mAbs Therapeutics YMAB Stock Holding History

Caligan Partners’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,342,609
Closed -$10.6M – 22
2025
Q2 		$10.6M Hold
2,342,609
– – 2.03% 11
2025
Q1 		$10.4M Buy
2,342,609
+574,627
+33% +$3.34M 2.17% 12
2024
Q4 		$13.8M Buy
1,767,982
+572,729
+48% +$6.98M 3.51% 9
2024
Q3 		$15.7M Buy
1,195,253
+613,175
+105% +$7.77M 4.98% 8
2024
Q2 		$7.03M Sell
582,078
-5,198
-0.9% -$70.2K 1.64% 11
2024
Q1 		$9.55M Sell
587,276
-461,149
-44% -$6.22M 2.52% 9
2023
Q4 		$7.15M Buy
1,048,425
+1,025,104
+4,396% +$5.93M 2.41% 8
2023
Q3 		$127K Buy
+23,321
New +$136K 0.06% 12

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caligan Partners's YMAB Position: Q3 2025 in Review

Caligan Partners sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 2,342,609 shares — an estimated $10.6M sold.

Caligan Partners first reported a position in YMAB in Q3 2023 and held it in 8 quarters. The position peaked at $15.7M in Q3 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Caligan Partners reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Caligan Partners sold 2,342,609 Y-mAbs Therapeutics shares in Q3 2025, an estimated $10.6M.
  • Caligan Partners first reported a position in Y-mAbs Therapeutics in Q3 2023 and held it in 8 quarters.
  • Caligan Partners's Y-mAbs Therapeutics position peaked at $15.7M in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Caligan Partners's 13F filing for Q3 2025, filed 14 Nov 2025.